gky
2021-12-16
Like
Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron<blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后，早盘继续上涨超过7%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
10
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690239979,"tweetId":"690239979","gmtCreate":1639668129324,"gmtModify":1639668129545,"author":{"id":3586473514667147,"idStr":"3586473514667147","authorId":3586473514667147,"authorIdStr":"3586473514667147","name":"gky","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690239979","repostId":1108384523,"repostType":4,"repost":{"id":"1108384523","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639667369,"share":"https://www.laohu8.com/m/news/1108384523?lang=zh_CN&edition=full","pubTime":"2021-12-16 23:09","market":"us","language":"en","title":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron<blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后，早盘继续上涨超过7%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1108384523","media":"Tiger Newspress","summary":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity a","content":"<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). </p><p><blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后，在早盘交易中继续上涨超过7%。该公司宣布了新的临床前数据，发布到预印本服务器bioRxiv，证明了新的COVID-19奥密克戎变种（B.1.1.529）的显著抗原转变的影响。</blockquote></p><p> A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. </p><p><blockquote>在接种疫苗和恢复期个体的血清中观察到针对奥密克戎的血浆中和活性显著降低。</blockquote></p><p> Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). </p><p><blockquote>研究人员还测试了44种单克隆抗体（mAb）的体外中和活性（其中8种目前已获得授权或批准）。</blockquote></p><p> Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.</p><p><blockquote>数据显示，Vir与葛兰素史克公司（纽约证券交易所股票代码：GSK）联合开发的sotrovimab和其他五种临床前单克隆抗体保留了对奥密克戎病的体外中和活性。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron<blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后，早盘继续上涨超过7%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron<blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后，早盘继续上涨超过7%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-16 23:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.<img src=\"https://static.tigerbbs.com/07fe5a6b831322eef2c479861ad70527\" tg-width=\"766\" tg-height=\"563\" width=\"100%\" height=\"auto\">The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). </p><p><blockquote>Vir Biotechnology在显示出对奥密克戎的中和活性后，在早盘交易中继续上涨超过7%。该公司宣布了新的临床前数据，发布到预印本服务器bioRxiv，证明了新的COVID-19奥密克戎变种（B.1.1.529）的显著抗原转变的影响。</blockquote></p><p> A significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. </p><p><blockquote>在接种疫苗和恢复期个体的血清中观察到针对奥密克戎的血浆中和活性显著降低。</blockquote></p><p> Researchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). </p><p><blockquote>研究人员还测试了44种单克隆抗体（mAb）的体外中和活性（其中8种目前已获得授权或批准）。</blockquote></p><p> Data demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.</p><p><blockquote>数据显示，Vir与葛兰素史克公司（纽约证券交易所股票代码：GSK）联合开发的sotrovimab和其他五种临床前单克隆抗体保留了对奥密克戎病的体外中和活性。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VIR":"Vir Biotechnology, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1108384523","content_text":"Vir Biotechnology continued to gain over 7% in morning trading after showing neutralizing activity against omicron.The company announced new preclinical data, published to the preprint server bioRxiv, demonstrating the impact of the significant antigenic shift of the new COVID-19 omicron variant (B.1.1.529). \nA significant reduction in plasma neutralizing activity was observed against omicron in sera from vaccinated and convalescent individuals. \nResearchers also tested the in vitro neutralizing activity of 44 monoclonal antibodies (mAbs) (eight of which are currently authorized or approved). \nData demonstrate that sotrovimab and five other preclinical mAbs, developed by Vir in conjunction with GlaxoSmithKline plc (NYSE: GSK), retained their in vitro neutralizing activity against omicron.","news_type":1,"symbols_score_info":{"VIR":0.9}},"isVote":1,"tweetType":1,"viewCount":2615,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690239979"}
精彩评论